Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product
- Authors
- Yoo, Dae Hyun; Oh, Choongseob; Hong, SeungSuh; Park, Won
- Issue Date
- Sep-2015
- Publisher
- TAYLOR & FRANCIS LTD
- Keywords
- ankylosing spondylitis; biosimilar; CT-P13; efficacy; infliximab; literature search; pharmacokinetics; rheumatoid arthritis; safety
- Citation
- EXPERT REVIEW OF CLINICAL IMMUNOLOGY, v.11, pp.S15 - S24
- Indexed
- SCIE
SCOPUS
- Journal Title
- EXPERT REVIEW OF CLINICAL IMMUNOLOGY
- Volume
- 11
- Start Page
- S15
- End Page
- S24
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156428
- DOI
- 10.1586/1744666X.2015.1090314
- ISSN
- 1744-666X
- Abstract
- Objective: To examine whether efficacy, safety and pharmacokinetic (PK) data observed with CT-P13 (Remsima (R); Inflectra (R)), an infliximab biosimilar, are similar to those from published reports with the reference medicinal product (RMP; Remicade (R)) in patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS). Methods: Literature searches were performed to identify clinical studies with infliximab RMP. Efficacy, safety and PK data were indirectly compared with data from head-to-head clinical trials of CT-P13 and RMP. Results: CT-P13 and RMP produce similar efficacy in patients with RA and AS when compared across clinical studies. There are no substantial differences in the incidence of infusion-related reactions, infections, serious infections, malignancy or lymphoma. PK data in patients with RA are similar in direct comparisons and comparisons with historical data. Conclusion: Efficacy, safety and PK data are highly comparable between CT-P13 and RMP, both in head-to-head clinical studies, and indirect comparisons with historical clinical data for RMP.
- Files in This Item
-
Go to Link
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156428)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.